Cenovus Energy Inc vs Smith & Nephew plc — how do they compare? Cenovus Energy Inc trades at $29.81 (market cap $55.00B), while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: Cenovus Energy Inc is far larger — about 4.4× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.
| CVE | SNN | |
|---|---|---|
Market Cap | $55.00B | $12.54B |
Sector | Energy | Health |
52-Week High | $31.80 | $38.70 |
52-Week Low | $14.83 | $28.73 |
Enterprise Value | $61.08B | $15.57B |
Dividend Yield | 2.09% | 2.65% |
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $29.56, up 4.64% with bullish technical momentum. The stock shows strong fundamentals with attractive valuation ratios (P/E 11.56, EV/EBITDA 5.77) and solid profitability (ROE 20.96%). Recent Q2 2026 earnings matched estimates with record oil sands production driving operational strength. Analyst consensus leans positive with 40.7% buy ratings despite mixed quarterly performance.
CVE presents value opportunity with robust cash flow generation and production growth, though faces commodity price volatility risks. Wall Street sentiment remains cautiously optimistic with institutional accumulation supporting upside potential. Key risks include oil price dependency and refining margin pressures that could impact earnings stability.
No Aura AI signal available yet.
Trailing returns across standard periods
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →